BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Vancouver - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Vancouver
X-ORIGINAL-URL:https://scienceinvancouver.com
X-WR-CALDESC:Events for Science in Vancouver
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T110000
DTEND;TZID=America/Vancouver:20220202T120000
DTSTAMP:20260619T074925
CREATED:20220128T194200Z
LAST-MODIFIED:20220131T192352Z
UID:20518-1643799600-1643803200@scienceinvancouver.com
SUMMARY:Gamma Fibrinogen and COVID-19; Who Knew?
DESCRIPTION:Dr. David Farrell \nProfessor of Surgery\, Oregon Health & Science University\nFounder and Chief Scientific Officer of Gamma Diagnostics \nIntroduction: COVID-19 disease progression can be accompanied by a “cytokine storm” that leads to secondary\nsequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been\nassociated with COVID-19 disease progression\, but have far too much daily intra-individual variability to be useful\nin tracking the course of the disease. In contrast\, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’\nFbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. The aims\nof the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical\ncenter in order to investigate its association with clinical measures of disease progression. \nHypothesis: Our hypothesis was that γ’ Fbg levels would be elevated in COVID-19 patients compared to historical\ncontrols\, and that the degree of elevation would be associated with disease severity. \nMethods: COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020\nand 8/1/2020. γ’ Fbg was measured using the GammaCoeur ELISA (Gamma Diagnostics\, Patent Pending). \nResults: Our results showed that ten out of the eighteen patients with COVID-19 had the highest levels of γ’ Fbg\never recorded. The previous highest γ’ Fbg level of 80.3 mg/dL was found in a study of 10\,601 participants in the\nARIC study. γ’ Fbg levels were significantly associated with the need for ECMO and mortality.\nConclusions: We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. This has several\nimportant clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding\nexosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a\nreservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential\nclinical implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin\nprophylaxis may be less effective than using other anticoagulants\, particularly direct thrombin inhibitors.
URL:https://scienceinvancouver.com/event/gamma-fibrinogen-and-covid-19-who-knew/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T110000
DTEND;TZID=America/Vancouver:20220202T120000
DTSTAMP:20260619T074925
CREATED:20220128T194200Z
LAST-MODIFIED:20220128T194200Z
UID:26503-1643799600-1643803200@scienceinvancouver.com
SUMMARY:Gamma Fibrinogen and COVID-19; Who Knew?
DESCRIPTION:Dr. David Farrell \nProfessor of Surgery\, Oregon Health & Science University\nFounder and Chief Scientific Officer of Gamma Diagnostics \nIntroduction: COVID-19 disease progression can be accompanied by a “cytokine storm” that leads to secondary\nsequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been\nassociated with COVID-19 disease progression\, but have far too much daily intra-individual variability to be useful\nin tracking the course of the disease. In contrast\, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’\nFbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. The aims\nof the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical\ncenter in order to investigate its association with clinical measures of disease progression. \nHypothesis: Our hypothesis was that γ’ Fbg levels would be elevated in COVID-19 patients compared to historical\ncontrols\, and that the degree of elevation would be associated with disease severity. \nMethods: COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020\nand 8/1/2020. γ’ Fbg was measured using the GammaCoeur ELISA (Gamma Diagnostics\, Patent Pending). \nResults: Our results showed that ten out of the eighteen patients with COVID-19 had the highest levels of γ’ Fbg\never recorded. The previous highest γ’ Fbg level of 80.3 mg/dL was found in a study of 10\,601 participants in the\nARIC study. γ’ Fbg levels were significantly associated with the need for ECMO and mortality.\nConclusions: We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. This has several\nimportant clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding\nexosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a\nreservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential\nclinical implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin\nprophylaxis may be less effective than using other anticoagulants\, particularly direct thrombin inhibitors.
URL:https://scienceinvancouver.com/event/gamma-fibrinogen-and-covid-19-who-knew-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T110000
DTEND;TZID=America/Vancouver:20220202T120000
DTSTAMP:20260619T074925
CREATED:20220128T194200Z
LAST-MODIFIED:20220128T194200Z
UID:28118-1643799600-1643803200@scienceinvancouver.com
SUMMARY:Gamma Fibrinogen and COVID-19; Who Knew?
DESCRIPTION:Dr. David Farrell \nProfessor of Surgery\, Oregon Health & Science University\nFounder and Chief Scientific Officer of Gamma Diagnostics \nIntroduction: COVID-19 disease progression can be accompanied by a “cytokine storm” that leads to secondary\nsequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been\nassociated with COVID-19 disease progression\, but have far too much daily intra-individual variability to be useful\nin tracking the course of the disease. In contrast\, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’\nFbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. The aims\nof the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical\ncenter in order to investigate its association with clinical measures of disease progression. \nHypothesis: Our hypothesis was that γ’ Fbg levels would be elevated in COVID-19 patients compared to historical\ncontrols\, and that the degree of elevation would be associated with disease severity. \nMethods: COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020\nand 8/1/2020. γ’ Fbg was measured using the GammaCoeur ELISA (Gamma Diagnostics\, Patent Pending). \nResults: Our results showed that ten out of the eighteen patients with COVID-19 had the highest levels of γ’ Fbg\never recorded. The previous highest γ’ Fbg level of 80.3 mg/dL was found in a study of 10\,601 participants in the\nARIC study. γ’ Fbg levels were significantly associated with the need for ECMO and mortality.\nConclusions: We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. This has several\nimportant clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding\nexosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a\nreservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential\nclinical implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin\nprophylaxis may be less effective than using other anticoagulants\, particularly direct thrombin inhibitors.
URL:https://scienceinvancouver.com/event/gamma-fibrinogen-and-covid-19-who-knew-3/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T110000
DTEND;TZID=America/Vancouver:20220202T120000
DTSTAMP:20260619T074925
CREATED:20220128T194200Z
LAST-MODIFIED:20220128T194200Z
UID:31201-1643799600-1643803200@scienceinvancouver.com
SUMMARY:Gamma Fibrinogen and COVID-19; Who Knew?
DESCRIPTION:Dr. David Farrell \nProfessor of Surgery\, Oregon Health & Science University\nFounder and Chief Scientific Officer of Gamma Diagnostics \nIntroduction: COVID-19 disease progression can be accompanied by a “cytokine storm” that leads to secondary\nsequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been\nassociated with COVID-19 disease progression\, but have far too much daily intra-individual variability to be useful\nin tracking the course of the disease. In contrast\, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’\nFbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. The aims\nof the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical\ncenter in order to investigate its association with clinical measures of disease progression. \nHypothesis: Our hypothesis was that γ’ Fbg levels would be elevated in COVID-19 patients compared to historical\ncontrols\, and that the degree of elevation would be associated with disease severity. \nMethods: COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020\nand 8/1/2020. γ’ Fbg was measured using the GammaCoeur ELISA (Gamma Diagnostics\, Patent Pending). \nResults: Our results showed that ten out of the eighteen patients with COVID-19 had the highest levels of γ’ Fbg\never recorded. The previous highest γ’ Fbg level of 80.3 mg/dL was found in a study of 10\,601 participants in the\nARIC study. γ’ Fbg levels were significantly associated with the need for ECMO and mortality.\nConclusions: We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. This has several\nimportant clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding\nexosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a\nreservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential\nclinical implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin\nprophylaxis may be less effective than using other anticoagulants\, particularly direct thrombin inhibitors.
URL:https://scienceinvancouver.com/event/gamma-fibrinogen-and-covid-19-who-knew-4/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T110000
DTEND;TZID=America/Vancouver:20220202T120000
DTSTAMP:20260619T074925
CREATED:20220128T194200Z
LAST-MODIFIED:20220128T194200Z
UID:32661-1643799600-1643803200@scienceinvancouver.com
SUMMARY:Gamma Fibrinogen and COVID-19; Who Knew?
DESCRIPTION:Dr. David Farrell \nProfessor of Surgery\, Oregon Health & Science University\nFounder and Chief Scientific Officer of Gamma Diagnostics \nIntroduction: COVID-19 disease progression can be accompanied by a “cytokine storm” that leads to secondary\nsequelae such as thrombosis and acute respiratory distress syndrome. Several inflammatory cytokines have been\nassociated with COVID-19 disease progression\, but have far too much daily intra-individual variability to be useful\nin tracking the course of the disease. In contrast\, we have shown that the inflammatory biomarker γ’ fibrinogen (γ’\nFbg) has a 6-fold lower coefficient of variability compared to other inflammatory markers such as hs-CRP. The aims\nof the study were to measure γ’ Fbg in serial blood samples from COVID-19 patients at a tertiary care medical\ncenter in order to investigate its association with clinical measures of disease progression. \nHypothesis: Our hypothesis was that γ’ Fbg levels would be elevated in COVID-19 patients compared to historical\ncontrols\, and that the degree of elevation would be associated with disease severity. \nMethods: COVID-19 patients at a tertiary care medical center were retrospectively enrolled between 3/16/2020\nand 8/1/2020. γ’ Fbg was measured using the GammaCoeur ELISA (Gamma Diagnostics\, Patent Pending). \nResults: Our results showed that ten out of the eighteen patients with COVID-19 had the highest levels of γ’ Fbg\never recorded. The previous highest γ’ Fbg level of 80.3 mg/dL was found in a study of 10\,601 participants in the\nARIC study. γ’ Fbg levels were significantly associated with the need for ECMO and mortality.\nConclusions: We found that COVID-19 patients can develop extraordinarily high levels of γ’ Fbg. This has several\nimportant clinical implications. γ’ Fbg contains a high affinity binding site for thrombin that binds to anion-binding\nexosite II on thrombin and protects it from inactivation by heparin. High levels of γ’ Fbg therefore provide a\nreservoir of heparin-resistant clot-bound thrombin when the γ’ Fbg is clotted. These findings have potential\nclinical implications regarding prophylactic anticoagulation of COVID-19 patients and suggest that heparin\nprophylaxis may be less effective than using other anticoagulants\, particularly direct thrombin inhibitors.
URL:https://scienceinvancouver.com/event/gamma-fibrinogen-and-covid-19-who-knew-5/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T170000
DTEND;TZID=America/Vancouver:20220202T180000
DTSTAMP:20260619T074925
CREATED:20220127T202811Z
LAST-MODIFIED:20220127T202811Z
UID:20476-1643821200-1643824800@scienceinvancouver.com
SUMMARY:Connect with Biotech and Life Sciences Professionals: Dr. Lorena Braid
DESCRIPTION:Connect with Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions\n\n\n\n\n\n\n\nThe SBN is pleased to announce our first event of the Connect with Biotech and Life Sciences Professional Series for 2022. We are delighted to be joined by Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions. \nDr. Lorena R. Braid is an Assistant Professor in the MBB department at Simon Fraser University. She holds a Canada Research Chair in Mesenchymal Stromal Cell Biology\, an award that recognizes exceptional early career researchers and emerging leaders in their fields. She is also the Founder and Chief Science Officer of Aurora BioSolutions\, where she leads a research team developing stem cell-based therapeutics for biological and chemical defence and severe burn injury. Dr. Braid was awarded a Ph.D. in Molecular Biology and Biochemistry by Simon Fraser University in 2011\, supported by seven competitive doctoral scholarships. In 2014\, Dr. Braid completed an NSERC Visiting Fellowship at Defence Research and Development Canada\, which explored the usefulness of stem cells for the Canadian Armed Forces and launched her current research programs. She is an active member of the International Society for Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT)\, BCRegMed and Life Sciences BC. \nThrough this opportunity\, students can expect to: \n\nLearn about careers in the life sciences and biotech industry\nEngage with Dr. Lorena Braid\nQ&A with Dr. Lorena Braid\n\nDue to the nature of the event\, there will be limited attendance. Those that are unable to secure a spot will be put on a waitlist.
URL:https://scienceinvancouver.com/event/connect-with-biotech-and-life-sciences-professionals-dr-lorena-braid/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2022/01/Lorena-Braid-SBN.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T170000
DTEND;TZID=America/Vancouver:20220202T180000
DTSTAMP:20260619T074925
CREATED:20220127T202811Z
LAST-MODIFIED:20220127T202811Z
UID:26502-1643821200-1643824800@scienceinvancouver.com
SUMMARY:Connect with Biotech and Life Sciences Professionals: Dr. Lorena Braid
DESCRIPTION:Connect with Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions\n\n\n\n\n\n\n\nThe SBN is pleased to announce our first event of the Connect with Biotech and Life Sciences Professional Series for 2022. We are delighted to be joined by Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions. \nDr. Lorena R. Braid is an Assistant Professor in the MBB department at Simon Fraser University. She holds a Canada Research Chair in Mesenchymal Stromal Cell Biology\, an award that recognizes exceptional early career researchers and emerging leaders in their fields. She is also the Founder and Chief Science Officer of Aurora BioSolutions\, where she leads a research team developing stem cell-based therapeutics for biological and chemical defence and severe burn injury. Dr. Braid was awarded a Ph.D. in Molecular Biology and Biochemistry by Simon Fraser University in 2011\, supported by seven competitive doctoral scholarships. In 2014\, Dr. Braid completed an NSERC Visiting Fellowship at Defence Research and Development Canada\, which explored the usefulness of stem cells for the Canadian Armed Forces and launched her current research programs. She is an active member of the International Society for Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT)\, BCRegMed and Life Sciences BC. \nThrough this opportunity\, students can expect to: \n\nLearn about careers in the life sciences and biotech industry\nEngage with Dr. Lorena Braid\nQ&A with Dr. Lorena Braid\n\nDue to the nature of the event\, there will be limited attendance. Those that are unable to secure a spot will be put on a waitlist.
URL:https://scienceinvancouver.com/event/connect-with-biotech-and-life-sciences-professionals-dr-lorena-braid-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2022/01/Lorena-Braid-SBN.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T170000
DTEND;TZID=America/Vancouver:20220202T180000
DTSTAMP:20260619T074925
CREATED:20220127T202811Z
LAST-MODIFIED:20220127T202811Z
UID:28117-1643821200-1643824800@scienceinvancouver.com
SUMMARY:Connect with Biotech and Life Sciences Professionals: Dr. Lorena Braid
DESCRIPTION:Connect with Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions\n\n\n\n\n\n\n\nThe SBN is pleased to announce our first event of the Connect with Biotech and Life Sciences Professional Series for 2022. We are delighted to be joined by Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions. \nDr. Lorena R. Braid is an Assistant Professor in the MBB department at Simon Fraser University. She holds a Canada Research Chair in Mesenchymal Stromal Cell Biology\, an award that recognizes exceptional early career researchers and emerging leaders in their fields. She is also the Founder and Chief Science Officer of Aurora BioSolutions\, where she leads a research team developing stem cell-based therapeutics for biological and chemical defence and severe burn injury. Dr. Braid was awarded a Ph.D. in Molecular Biology and Biochemistry by Simon Fraser University in 2011\, supported by seven competitive doctoral scholarships. In 2014\, Dr. Braid completed an NSERC Visiting Fellowship at Defence Research and Development Canada\, which explored the usefulness of stem cells for the Canadian Armed Forces and launched her current research programs. She is an active member of the International Society for Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT)\, BCRegMed and Life Sciences BC. \nThrough this opportunity\, students can expect to: \n\nLearn about careers in the life sciences and biotech industry\nEngage with Dr. Lorena Braid\nQ&A with Dr. Lorena Braid\n\nDue to the nature of the event\, there will be limited attendance. Those that are unable to secure a spot will be put on a waitlist.
URL:https://scienceinvancouver.com/event/connect-with-biotech-and-life-sciences-professionals-dr-lorena-braid-3/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2022/01/Lorena-Braid-SBN.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T170000
DTEND;TZID=America/Vancouver:20220202T180000
DTSTAMP:20260619T074925
CREATED:20220127T202811Z
LAST-MODIFIED:20220127T202811Z
UID:31200-1643821200-1643824800@scienceinvancouver.com
SUMMARY:Connect with Biotech and Life Sciences Professionals: Dr. Lorena Braid
DESCRIPTION:Connect with Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions\n\n\n\n\n\n\n\nThe SBN is pleased to announce our first event of the Connect with Biotech and Life Sciences Professional Series for 2022. We are delighted to be joined by Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions. \nDr. Lorena R. Braid is an Assistant Professor in the MBB department at Simon Fraser University. She holds a Canada Research Chair in Mesenchymal Stromal Cell Biology\, an award that recognizes exceptional early career researchers and emerging leaders in their fields. She is also the Founder and Chief Science Officer of Aurora BioSolutions\, where she leads a research team developing stem cell-based therapeutics for biological and chemical defence and severe burn injury. Dr. Braid was awarded a Ph.D. in Molecular Biology and Biochemistry by Simon Fraser University in 2011\, supported by seven competitive doctoral scholarships. In 2014\, Dr. Braid completed an NSERC Visiting Fellowship at Defence Research and Development Canada\, which explored the usefulness of stem cells for the Canadian Armed Forces and launched her current research programs. She is an active member of the International Society for Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT)\, BCRegMed and Life Sciences BC. \nThrough this opportunity\, students can expect to: \n\nLearn about careers in the life sciences and biotech industry\nEngage with Dr. Lorena Braid\nQ&A with Dr. Lorena Braid\n\nDue to the nature of the event\, there will be limited attendance. Those that are unable to secure a spot will be put on a waitlist.
URL:https://scienceinvancouver.com/event/connect-with-biotech-and-life-sciences-professionals-dr-lorena-braid-4/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2022/01/Lorena-Braid-SBN.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220202T170000
DTEND;TZID=America/Vancouver:20220202T180000
DTSTAMP:20260619T074925
CREATED:20220127T202811Z
LAST-MODIFIED:20220127T202811Z
UID:32660-1643821200-1643824800@scienceinvancouver.com
SUMMARY:Connect with Biotech and Life Sciences Professionals: Dr. Lorena Braid
DESCRIPTION:Connect with Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions\n\n\n\n\n\n\n\nThe SBN is pleased to announce our first event of the Connect with Biotech and Life Sciences Professional Series for 2022. We are delighted to be joined by Dr. Lorena Braid\, Assistant Professor in the MBB Department at SFU\, Founder and Chief Science Officer of Aurora BioSolutions. \nDr. Lorena R. Braid is an Assistant Professor in the MBB department at Simon Fraser University. She holds a Canada Research Chair in Mesenchymal Stromal Cell Biology\, an award that recognizes exceptional early career researchers and emerging leaders in their fields. She is also the Founder and Chief Science Officer of Aurora BioSolutions\, where she leads a research team developing stem cell-based therapeutics for biological and chemical defence and severe burn injury. Dr. Braid was awarded a Ph.D. in Molecular Biology and Biochemistry by Simon Fraser University in 2011\, supported by seven competitive doctoral scholarships. In 2014\, Dr. Braid completed an NSERC Visiting Fellowship at Defence Research and Development Canada\, which explored the usefulness of stem cells for the Canadian Armed Forces and launched her current research programs. She is an active member of the International Society for Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT)\, BCRegMed and Life Sciences BC. \nThrough this opportunity\, students can expect to: \n\nLearn about careers in the life sciences and biotech industry\nEngage with Dr. Lorena Braid\nQ&A with Dr. Lorena Braid\n\nDue to the nature of the event\, there will be limited attendance. Those that are unable to secure a spot will be put on a waitlist.
URL:https://scienceinvancouver.com/event/connect-with-biotech-and-life-sciences-professionals-dr-lorena-braid-5/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinvancouver.com/wp-content/uploads/sites/1/2022/01/Lorena-Braid-SBN.png
END:VEVENT
END:VCALENDAR